Asia OneHealthcare: TPG Inc explores $7.5B business exit strategy via sale or IPO

Private equity giant TPG Inc is reportedly evaluating strategic exit options for its ownership stake in Asia OneHealthcare, including a potential sale or initial public offering (IPO) that could value the healthcare platform at around MYR 30 billion (≈ $7.5 billion), according to Private Equity Insights. No final decision has been made, and the discussions remain in the early stages.

The deliberations are in early stages, with TPG consulting financial advisers to assess the merits of a public listing versus a sale to a strategic or financial buyer. No final decision has been made, and TPG could opt to retain its stake if market conditions or valuation expectations change.

Strategic exit considerations: sale vs. IPO exit

Asia OneHealthcare operates as a medical services platform with its headquarters in Kuala Lumpur, Malaysia. The company traces its origins to Columbia Asia Healthcare, which TPG and Hong Leong Group acquired in 2019 for approximately US$1.2 billion. Since then, the platform has expanded both organically and through acquisitions, including the 2023 purchase of hospital units from Ramsay Health Care Ltd. and Sime Darby Bhd.

TPG’s potential exit routes include:

1. Sale to a strategic or private equity buyer: Which could deliver immediate liquidity and strong returns for limited partners.
2. IPO: Listing the company publicly, potentially in Malaysia or another regional market, to capture growth valuation in public markets.

Advisers working on a separate listing for Sunway Healthcare Holdings Bhd. — expected to be one of Malaysia’s largest recent IPOs — are among those advising TPG on potential market timing, valuation benchmarks, and regulatory considerations.

Asia OneHealthcare’s growth and market position

Under TPG’s ownership, Asia OneHealthcare has established a stronger regional footprint in private healthcare services. The platform combines multiple hospital assets and healthcare service units, addressing a growing demand for private healthcare in Southeast Asia — driven by rising middle‑class income, increased insurance penetration, and evolving patient expectations for quality care.

These drivers have made Asia OneHealthcare an attractive asset class for both strategic and financial investors, supporting debates around valuation expectations and exit timing.

Investment and exit dynamics in private equity healthcare platforms

TPG’s consideration of both sale and IPO options reflects broader trends in private equity dealmaking:

Healthcare as a resilient asset class: Healthcare services platforms often attract strong buyer interest due to steady demand and defensible business models.

IPO windows matter: Public market conditions — especially in Asia — influence whether firms pursue an IPO exit versus a trade sale at favorable multiples.

Institutional alignment: TPG’s ongoing discussions with advisers, including those working on adjacent listings like Sunway Healthcare, suggest a coordinated approach to timing and valuation.

For limited partners and co‑investors, the decision will hinge on relative value capture — selling now at a strong multiple versus staying invested to benefit from future operational gains or higher public market valuations.

Broader market context

The move also comes amid heightened activity in private equity‑owned healthcare assets across Asia. TPG itself has been active in Southeast Asia, with recent transactions including a majority stake sale in XCL Education Holdings Pte. to KKR & Co. — another sign that larger buy‑side interest persists in regional platforms.

The broader trend points to a maturing private capital ecosystem in Asia, where early and mid‑stage PE investors are increasingly considering public exits or strategic sales to capture value and redeploy capital into new sectors or growth markets.

What this means for investors

For institutional investors, co‑investors, and market watchers, TPG’s exploration of sale or IPO exit options for Asia OneHealthcare offers several takeaways:

1. Business exit strategy flexibility: TPG’s case illustrates how PE firms weigh multiple exit paths to unlock value, rather than defaulting to one mechanism.
2. Healthcare demand tailwinds: Private healthcare platforms in Asia may continue to attract robust capital interest due to structural growth dynamics.
3. Public market timing matters: The performance of comparable healthcare IPOs — like Sunway Healthcare — will likely inform TPG’s final decision.

As TPG evaluates a strategic sale or IPO exit for Asia OneHealthcare, the potential $7.5 billion exit underscores the growing appeal of healthcare platforms in Asia for private equity investors. The decision highlights how fund managers weigh market timing, operational performance, and investor returns when choosing between public listings and private sales. For early and institutional investors, the deal serves as a case study in capturing value from high-growth sectors, demonstrating that Asia’s healthcare market remains a compelling arena for private equity investment and strategic exits.

About UCapital.com

UCapital is a global financial intelligence and news platform. It combines timely market coverage and in-depth analysis with access to curated deal opportunities, connecting investors and financial professionals to private market activity.